-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 22, Buchang Pharmaceutical announced that the clinical trial application for "BC004 for injection" of its holding subsidiary Luzhou Buchang Bio-Pharmaceutical Co.
BC004 for injection is a recombinant anti-HER2/CD3 humanized bispecific antibody drug, which is mainly used for the treatment of HER2-positive advanced solid tumors, including HER2-positive breast cancer, gastric cancer/gastroesophageal junction adenocarcinoma,
As of December 31, 2021, Luzhou Buchang has invested approximately RMB 48.